{"id":531076,"date":"2021-02-20T19:04:02","date_gmt":"2021-02-20T19:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531076"},"modified":"2021-02-20T19:04:02","modified_gmt":"2021-02-20T19:04:02","slug":"raynauds-disease-market-size-share-epidemiology-and-competitive-insights-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/raynauds-disease-market-size-share-epidemiology-and-competitive-insights-2030-by-delveinsight_531076.html","title":{"rendered":"Raynaud’s Disease Market Size, Share, Epidemiology and Competitive Insights 2030 by DelveInsight"},"content":{"rendered":"
\"Raynaud's<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Raynauds Disease – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Raynauds Disease, historical and forecasted epidemiology as well as the Raynauds Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Raynaud’s Disease Market Insights, Epidemiology and Market Forecast 2030<\/strong><\/a>.<\/p>\n

DelveInsight’s “Raynauds Disease – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>“<\/span> report delivers an in-depth understanding of the Raynauds Disease, historical and forecasted epidemiology as well as the Raynauds Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

In response to cold temperatures, the body adapts by restricting blood flow to the skin. This is done as a thermoregulating mechanism to prevent further loss of body heat and to sustain the core body temperature. In Raynaud phenomenon, blood-flow restriction occurs during cold temperatures and emotional stress. Specifically, in Raynaud phenomenon, there is vasoconstriction of the digital arteries and cutaneous arterioles. This phenomenon was first described by Maurice Raynaud in 1862 and later studied by Sir Thomas Lewis in 1930. Overall, Raynaud phenomenon is a transient and peripheral vasoconstrictive response to cold temperatures or emotional stress. Raynaud phenomenon can be categorized as either primary or secondary.<\/div>\n
 <\/div>\n
In the primary Raynaud phenomenon, an increase in alpha-2 adrenergic sensitivity in the digital and cutaneous vessels results in the vasoconstrictive response to cold temperatures and emotional stress. Alpha-2 adrenergic receptors are present on the distal arterial smooth muscles of the digits and affected by the sympathetic nervous system. In secondary Raynaud phenomenon, the underlying disease is the factor that disrupts normal vessel reactivity to cold temperatures. Usually, the endothelial function of the digital and cutaneous vessels is compromised leading to eventual vasoconstriction with resulting tissue ischemia. <\/div>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/raynauds-disease-market<\/span><\/a><\/strong><\/p>\n

“The Raynaud’s Disease market size<\/a> in the 7MM was found to be XXXX Million in 2017.”<\/strong><\/p>\n

Table of contents:<\/strong><\/p>\n

1 Key Insights
2 Executive Summary of Raynaud’s Disease
3 Raynaud’s Disease Market Overview at a Glance
4 Disease Background and Overview: Raynaud’s Disease
5 Case Reports
6 Raynaud’s Disease Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Raynaud’s Disease Treatment and Medical Practices
11 Unmet needs
12 Raynaud’s Disease Marketed Drugs
13 Raynaud’s Disease Emerging Drugs
14 Raynaud’s Disease 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Raynaud’s Disease Market Drivers
19 Raynaud’s Disease Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

Download report: https:\/\/www.delveinsight.com\/report-store\/raynauds-disease-market<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research LLP DelveInsight’s “Raynauds Disease – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Raynauds Disease, historical and forecasted epidemiology as well as the Raynauds Disease market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531076","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531076"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}